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Abstract: Aims: To explore whether Chlamydia pneumoniae, Cytomegalovirus and Herpes Simplex Virus type 1 could 
be detected in large and small cerebral arteries, as well as in an area of brain parenchyma where white matter lesions (leu-
koaraiosis) can be found, in patients with clinically unmanifested cerebrovascular atherosclerosis. Methods and results: 
Arterial specimens from the basilar artery and middle cerebral artery, and brain samples from the basal ganglia and 
periventricular white matter were obtained. Neuropathological changes were assessed in Haematoxylin-Eosin stained sec-
tions. Polymerase chain reaction (PCR) was performed on paraffin embedded sections. Subsequently, we performed im-
munohistochemical staining on samples, which were found positive in PCR. We failed to detect C. pneumoniae, CMV, or 
HSV-1, in any of the cerebral large vessels. In the brain tissue, we found only one case positive for CMV, and one for C. 
pneumoniae. Conclusions: our findings suggest a limited role for C. pneumoniae, CMV and HSV-1 in cerebral large and 
small vessel atherosclerosis. 
Keywords: Chlamydia pneumoniae, Cytomegalovirus, Herpes Simplex Virus type 1, small vessel disease, brain. 
INTRODUCTION 
 Atherosclerosis is an inflammatory disease. The ‘re-
sponse to injury’ hypothesis proposes endothelial dysfunc-
tion as the initiating factor, followed by influx of monocyte-
derived macrophages and T-lymphocytes [1]. Over the past 
decade there has been much speculation about the role of 
microorganisms in the activation and maintenance of this 
inflammatory response. The microorganisms most exten-
sively investigated in this context are Chlamydia pneumo-
niae (C. pneumoniae) and Cytomegalovirus (CMV) [2-4]. 
Some reports have described the role of Herpes Simplex 
Virus type 1 (HSV-1) as well [5, 6]. For both C. pneumoniae 
and CMV, the relationship between infection and atheroscle-
rosis was first established in the late 80’s [7, 8]. Two studies 
showed that patients suffering from cardiovascular disease 
more often had antibodies against the microorganisms than a 
matched control group. Pathological studies have shown the 
presence of C. pneumoniae [9], CMV [10] and HSV-1 [11, 
12], in arterial specimens from various sites. One study 
showed the presence of all three microorganisms in the same 
carotid arterectomy sample [13]. Only a few studies report 
on the relationship between infection with these microorgan-
isms and cerebrovascular disease (CVD) [14-17]. Even less 
attention has been paid to the actual presence of these micro-
organisms in the large cerebral vessels, with only a few re-
ports on the presence of C. pneumoniae in these vessels [18-
20]. In the study by Rassu et al. [19], the presence of CMV 
was studied as well but the presence of HSV-1 has never 
been investigated in this context. 
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 Factors involved in CVD may differ from those in car-
diovascular disease. CVD may broadly be divided into two 
entities: large vessel disease (LVD) and small vessel disease 
(SVD). LVD, which is due to atherosclerosis of the larger 
cerebral vessels, causes mainly larger, usually called territo-
rial infarcts, which often involve the cortex. The risk factors 
for large vessel disease are similar to those of cardiovascular 
disease in general. SVD causes small infarcts, less than 15 
mm in diameter on cerebral imaging, which are located in 
the deep brain structures (basal ganglia and internal capsule) 
or the pons; these are often referred to as lacunar infarcts. 
SVD is also the cause of more diffuse damage to the white 
matter of the brain: leukoaraiosis. The clinical manifestation 
of either LVD or SVD is consistent over time [21]. There-
fore, it is rational to investigate potential causes or factors 
that sustain these two types of cerebrovascular diseases sepa-
rately. The role of C. pneumoniae, CMV and HSV-1 in SVD 
has never been investigated in this respect.  
 The aim of this study was to investigate whether the 
presence of C. pneumoniae, CMV and HSV-1 could be es-
tablished in the large and small cerebral arteries, as well as in 
brain parenchyma where leukoaraiosis can be found, in cases 
with pathological evidence of cerebrovascular atherosclero-
sis. 
MATERIALS AND METHODS 
Autopsy specimens 
 Included in the study were autopsy specimens from ten 
men and nine women, ranging from 33 to 80 years of age 
(median 70). Patient characteristics are summarized in Table 
1. At autopsy the brain was removed, and immersed in 10% 
buffered formaldehyde for at least two weeks. The large 
cerebral vessels were dissected after which the brain was cut 
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in frontal sections. The material was embedded in paraffin 
and used for routine neuropathological examination.  
Table 1. Presence and Severity of SVD and LVD, Age, Sex and 
Cause of Death in the 19 Studied Cases. F: Female, M: 
Male, NA: Not Assessed 
Case Sex Age LVD SVD Cause of death 
1 F  80.0 + NA Hemorrhagic stroke 
2 M  51.0 0 NA Hepatic encephalopathy 
3 M  87.0 ++ + Ischaemic stroke 
4 M  73.0 +++ NA Cerebellar haematoma 
5 F  57.0 + NA Gastrointestinal bleeding 
6 M  74.0 ++ + Cardiac arrest 
7 M  62.0 + + Respiratory arrest 
8 M  63.0 +++ +++ Hemorrhagic stroke 
9 M  47.0 + ++ Cerebral metastasis 
10 M  39.0 + 0 Sepsis 
11 M  81.0 +++ + Ischaemic stroke 
12 F  70.0 ++ + Non-Hodgkin lymphoma 
13 F  33.0 + + Myocardial infarction 
14 M  79.0 +++ ++ Hemorrhagic stroke 
15 F  86.0 +++ + Post op bleeding 
16 M  69.0 ++ +++ Myocardial ischaemia 
17 F  86.0 +++ + Meningitis 
18 M  65.0 + + Myocardial ischaemia 
19 M  79.0 ++ 0 Aortic dissection 
 
 For this study, specimens were obtained from the areas 
supplied by small vessels, i.e. the basal ganglia and the 
periventricular white matter. Arterial specimens included the 
distal 3-cm of the basilar artery (BA) and the proximal 3 cm 
of the middle cerebral artery (MCA), directly after it 
branches from the internal carotid artery. Arterial sites show-
ing macroscopic signs of atherosclerosis were also included. 
The large vessels were embedded longitudinally.  
 Paraffin embedded material was used for Haematox-
ylin/Eosin (HE) staining, immunohistochemistry (IHC) 
staining and polymerase chain reaction (PCR). Ten 5 μm 
sections were cut, followed by a 50 μm section. This was 
serially continued until all material was used. The first of 
each 5 μm section was used for HE staining; the following 5 
μm section was used for IHC. The 50 μm sections were used 
for PCR; three 50 μm sections were pooled in one serum 
tube and stored at 4 °C until further processing 
Serology 
 Post-mortem serum samples were taken from each case. 
The sera were kept at –20 °C until further processing. C. 
pneumoniae serology was performed using a micro immuno 
fluorescence test (Labsystems, Helsinki, Finland). Samples 
were considered positive when titres were 1:32 or higher. 
 CMV and HSV-1 antibodies were aimed to detect using 
commercially available Enzyme Linked Immunoabsorbent 
Assays (ELISA) used in routine diagnosis of these antibodies 
(Serion, Germany). Samples were considered positive when 
titres were > 30. 
Tissue Preparation and PCR Analysis 
 Tissue preparation and DNA extraction was performed 
using the technique described by Gass et al. [22] Prior to 
DNA isolation, the sections were deparaffinised by adding 
700 μl of xylol. After this they were vibrated for 1 minute 
using the Vortex® and centrifuged for ten minutes at 40000 
rotations per minute (rpm) in a Micro 22R rotator. This 
procedure was repeated. After deparaffination, the sections 
were rehydrated by adding 70% ethanol. Again, the samples 
were vibrated using the Vortex® for 1 minute and centri-
fuged for ten minutes at 40000 rpm in the Micro 22R rota-
tor. This also was done twice. Following deparaffination, 
DNA was extracted from brain tissue with the Wizard Ge-
nomic DNA purification kit (Promega, Germany). Then, the 
purified DNA was subjected to PCR aiming to detect either 
C. pneumoniae, CMV or HSV-1 DNA.  
 All PCRs were performed in a total volume of 50 :l, con-
taining 1 μg purified DNA, 0.1 mM of each dNTP, 0.5 μM 
of each primer:  
* C. pneumoniae: CPC, 5’-TTA TTA ATT GAT GGT 
ACA ATA-3’; antisense CPD, 5’-ATC TAC GGC 
AGT AGT ATA GTT-3’; 
* CMV: sense 5’ GCG GGA GAT GTG GAT GGC 
TTG TAT TAA GGA 3’-antisense 5’-GCA GAC 
TCT CAG AGG ATC GGC CCC C-3’; 
* HSV-1: sense 5’-GCA TCG TCG AGG TGG AC-3’; 
antisense 5’-CCT GCC ACT TGG TCA TG-3’ DNA 
 Amplification was carried out in a Perkin Elmer 9600 
thermal cycler, using the following cycling conditions:  
* C. pneumoniae: 37 
o 
C for ten minutes and 95 
o 
C for 
fifteen minutes. 20 cycles of “Touchdown PCR” were 
performed from 60 
o 
C to 50 
o 
C, followed by 40 cy-
cles of 1 minute at 94 
o 
C, 50 
o 
C, and 72 
o 
C. 
* CMV: 37 
o 
C for ten minutes and 95 
o 
C for fifteen 
minutes. PCR was performed in 50 cycles of 30 sec-
onds at 95 
o 
C, 70 
o 
C and 72 °C. 
* HSV-1: 37 
o 
C for ten minutes and 95 
o 
C for fifteen 
minutes. PCR was performed in 50 cycles of 30 sec-
onds at 94 
o 
C, 69 
o 
C and 72 °C.  
 After this the PCR products were kept overnight at  
15 
o
C. The PCR products were resolved in a 2% agarose gel, 
stained with ethidium bromide, and photographed.  
Histology and Immunohistochemistry 
 Five μm paraffin sections were used for HE staining, 
performed using standard procedures. The morphological 
changes were evaluated on routinely processed 5 μm HE 
sections. The evaluation of the vascular changes was per-
formed by the neuropathologist (BK), who was blinded for 
the case characteristics. Cerebral large vessel atherosclerosis 
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was graded as mild (+) moderate (++), and severe (+++) 
when intimal fibrosis, fibro-atheromatous plaques, or fibro-
atheromatous plaques with calcification were present, re-
spectively. The changes in the small cerebral vessels were 
recorded as
 
mild (+), moderate (++), or severe (+++) in each
 
HE stained block from the basal ganglia or periventricular 
white matter. Mild SVD was defined as concentric vessel 
wall
 
thickening in small arteries and arterioles but with mild 
or minimal luminal narrowing, moderate SVD implied sig-
nificant luminal
 
narrowing, but with the lumen spanning 
more than half the total external
 
diameter. In severe SVD the 
internal vessel diameter
 
was less than half of the external 
diameter [23]. Apart from this the presence of lacunar in-
farcts was recorded.  
 Since the PCR is the most sensitive technique to detect 
the presence of microorganisms, we first used the PCR to 
detect CMV, C. pneumoniae and HSV-1. In cases that were 
positive by PCR, IHC was performed, to identify the specific 
cells infected with either microorganism. For C. pneumo-
niae, the RR402 mouse monoclonal antibody (against a ma-
jor outer membrane protein MOMP of C. pneumoniae) 
(DAKO, Denmark) was used as primary antibody (dilution 
1:50). This antibody is specific for C. pneumoniae [24]. 
Normal mouse ascites was used as a negative control. Five 
μm thick paraffin embedded sections were pre-incubated 
with 2% Bovine Serum Antigen (BSA) in PBS to block non 
specific staining, after which the slides were incubated with 
the primary antibody or normal mouse ascites at 37 °C, for 
one hour, each slide containing two samples, one for the an-
tibody and one for the control, respectively. After washing in 
Phosphate Buffered Saline (PBS), the sections were incu-
bated with the secondary antibody: biotinylated goat anti-
mouse serum (DAKO, Denmark). Immunostaining was per-
formed by the avidin-biotin alkalic phosphatase method 
(DAKO, Denmark). Fast red was used as a chromogen, after 
which the sections were counterstained with haematoxylin. 
Infected Hep-2 cells were used as a positive control; mock-
infected Hep-2 cells were used as negative control. The same 
method was used for the immunohistochemical staining of 
CMV using an antibody against the E13 gene of human 
CMV as the primary antibody (Argene Biosoft, France) (di-
lution1: 50). 
RESULTS 
 The results are summarized in Table 1. 
Cerebral Large Vessels 
 From all cases, either the BA or MCA was available for 
assessment of cerebral large vessel atherosclerosis. Both 
vessels could be examined in 14/19 cases. In 5 cases cerebral 
vessels other then the BA or MCA showed macroscopic 
signs of atherosclerosis; these were three vertebral artery 
samples, one anterior cerebral artery, and the intracranial 
part of one internal carotid artery, respectively. In all but one 
case microscopic atherosclerotic changes were seen in at 
least one of the arteries. The case without atherosclerotic 
changes was a 51-year old male who had died from hepatic 
encephalopathy. In total, 43 arterial specimens from 19 pa-
tients could be investigated. Four of these samples (9%) 
were without atherosclerotic changes. In the remaining 91% 
atherosclerotic changes varied from intima fibrosis (35%), 
and fibro-atheromatous plaques (35%), to fibro-
atheromatous plaques with calcification (21%). Territorial 
cerebral infarction as a result of large vessel atherosclerosis 
was seen in two cases. More severe atherosclerosis was ob-
served in cases that had died from vascular causes, but this 
difference was not significant. Using the PCR method, we 
failed to establish the presence of C. pneumoniae, CMV, or 
HSV-1 in any of the cerebral large vessels. No immunohis-
tochemical staining was done on the cerebral large vessel 
specimens, since we only performed IHC on specimens posi-
tive in PCR.  
Cerebral Small Vessels, Basal Ganglia, Periventricular 
White Matter  
 In 15/19 cases cerebral small vessel samples and brain 
tissue were available for neuropathological examination. 
SVD was present in either the basal ganglia or periventricu-
lar white matter in 13 of these. SVD was mostly observed in 
the basal ganglia, with some degree of SVD (changes to the 
cerebral small vessels or lacunar infarction) present in 9/15 
cases. Signs of SVD in the periventricular white matter were 
found in 5/15 cases. When SVD was present, it was graded 
as mild, with concentric vessel wall
 
thickening in small arter-
ies and arterioles but with mild or minimal luminal narrow-
ing, in 71 percent of the samples. Lacunar infarcts were 
found in 7/15 basal ganglia, and in 2/15 of periventricular 
white matter samples. We found only one case positive for 
CMV, and one for C. pneumoniae. In the first case, which 
had died of basilar artery thrombosis, CMV was found in the 
basal ganglia. In the second case, which died from a post-
operative bleeding after a laparotomy, C. pneumoniae was 
found in the periventricular white matter (Fig. 1). IHC 
showed the presence of C. pneumoniae in the PCR positive 
C. pneumoniae was present in ganglion cells (Fig. 2) and 
underneath the basal membrane, probably in myo-fibrocytes 
of the medial lamina of the arteriole (Fig. 3). By IHC the 
presence of CMV in the PCR positive sample could not be 
confirmed. Since PCR did not show any HSV-1 DNA in any 
of the samples, IHC for HSV-1 was not performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). C. pneumoniae PCR of periventricular whiter matter. Lane 
2 shows sample positive for C. pneumoniae at the 207 bp site (case 
15), Lanes 1 and 3 are negative samples (cases 13 and 14), lane 4: 
negative control, lane 5: positive control (C. pneumoniae infected 
Hep-2 cells), lane 6: base pair ladder, lane 7 and 8: test efficiency 
controls. 
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Fig. (2). Immunohistochemical staining, showing the presence of C. 
pneumoniae (arrows) in ganglion cells of the brain. Magnification 
x400. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Immunohistochemical staining, showing the presence of C. 
pneumoniae (arrow) underneath the basal membrane, probably in 
myo-fibrocytes of the medial lamina of the arteriole. Magnification 
x 400. 
 
Serology 
 IgG antibodies against C. pneumoniae were found in 
15/19 cases, IgG antibodies against HSV-1 in 16 and, IgG 
antibodies against CMV in 18. 
 Both cases that were found positive in PCR had antibod-
ies against CMV and C. pneumoniae. 
DISCUSSION 
Cerebral Large Vessel Disease 
 We failed to establish the presence of C. pneumoniae, 
CMV or HSV-1 DNA in large vessel samples of patients 
who died from various causes, but who all had signs of athe-
rosclerosis in at least one of the cerebral arteries, varying 
from intima fibrosis to fully developed atherosclerotic 
plaques with calcifications.  
 The presence of microorganisms in atherosclerotic 
plaques is patchy. Therefore, detection rates vary between 
studies [25]. Even if the vessels are embedded and processed 
longitudinally, and are of considerable length like in our 
study, not all the material is used in the PCR. Therefore, al-
though the PCR can detect up to one copy of DNA, false 
negative results may occur as a result of “sampling error”. 
This patchy presence of microorganisms is also responsible 
for the differences in results between IHC and PCR [26]. In 
one study, that used IHC to detect C. pneumoniae in the 
cerebral vessels of asymptomatic patients, C. pneumoniae 
was found in only two percent, even though these specimens 
showed various signs of atherosclerosis of the MCA [18].  
 When PCR was used to detect C. pneumoniae in fully 
developed atherosclerotic lesions, the microorganism was 
found in one third of the vessels [20]. For PCR, frozen sec-
tions as well as formalin fixed sections are used. Deparaf-
finisation of formalin fixed sections, which is needed to al-
low isolation of DNA from the material, might result in loss 
of DNA. However, Gass et al. showed that correctly proc-
essed material even when embedded in paraffin should pro-
vide enough DNA to establish the presence of the microor-
ganism, even in samples that have been stored for years [22]. 
Since we used the same technique to process the material 
and extract the DNA, and found no inhibition, we assume 
that our technique is sufficient enough to detect the three 
microorganisms in formalin fixed brain tissue. Our PCR’s 
are among the most sensitive, with C. pneumoniae being 
detected from up to one copy of DNA and both CMV and 
HSV-1 from up to 10 copies of DNA. The presence of CMV 
DNA in atherosclerotic tissue was first reported in a study 
using formalin fixed sections; CMV was found in 94 percent 
of the samples [27]. Studies on the presence of CMV in athe-
rosclerotic tissue showed a prevalence varying from 0% [28] 
to 94% [27]. Using frozen sections or paraffin embedded 
tissue for PCR analysis does not influence the prevalence of 
CMV. Therefore, it is unlikely that the absence of microor-
ganisms in our samples is due to the fact that we used forma-
lin fixed sections. 
 One limitation of our study is that we did not compare 
the presence of C. pneumoniae, CMV and HSV-1 DNA in 
other arterial sites in the human body. In one study, that 
compared the presence of C. pneumoniae in various arterial 
sites, significant differences were found in chlamydial pres-
ence, with the highest rate in the abdominal aorta (67%), and 
much lower rates in the and cerebral (2%) arteries. Several 
studies have shown a higher prevalence of C. pneumoniae 
DNA in carotid arteries compared to intracranial arteries, 
with prevalence varying from 15% to 83%[29-32]. CMV 
was found in 36% of atherosclerotic carotid arteries, HSV-1 
in 11% [13]. Even though our results do not support the hy-
pothesis that C. pneumoniae, CMV and HSV-1 play a condi-
tional role in the generation of cerebral atherosclerosis, we 
cannot rule out that these microorganisms do play a role in 
clinically manifest large vessel disease, since the majority of 
our patient group was asymptomatic. Furthermore, these 
microorganisms do seem to play a role in the initiation of 
carotid atherosclerosis, which is a risk factor for clinical 
stroke.  
Cerebral Small Vessel Disease 
 We detected C. pneumoniae DNA in brain tissue in one 
out of 19 cases, and found CMV DNA in one other case. We 
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could not detect HSV-1 DNA in any of the samples. PCR is 
considered the gold standard for detection of microorgan-
isms, but it has several disadvantages. Since PCR techniques 
become more and more sensitive, even very small amounts 
of DNA can be detected, leaving the question open for the 
clinical relevance of some findings. Our PCR’s are among 
the most sensitive, with C. pneumoniae being detected from 
up to one copy of DNA and both CMV and HSV-1 from up 
to 10 copies of DNA. Another disadvantage is that PCR does 
not localize the microorganism within the tissue. In an at-
tempt to localize the microorganisms we used immunohisto-
chemistry on the samples positive in PCR, C. pneumoniae 
was found in the basal ganglia, more specifically in ganglion 
cells and underneath the basal membrane of a small arteriole. 
The CMV presence could not be confirmed by IHC.  
 Studies on the prevalence of C. pneumoniae, CMV and 
HSV-1 in brain tissue, detected these microorganisms in 95 
[33], 94 [34] and 67 [35] percent. However, the brain sam-
ples tested in these studies came from the frontal and tempo-
ral cortex, whereas all the patients had clinically manifest 
dementia. No studies have been reported on the presence of 
C. pneumoniae, CMV or HSV-1 in the basal ganglia or the 
periventricular white matter, the areas of the brain supplied 
by small vessels.  
 Our results do not point at an important role of the mi-
croorganisms in the generation of SVD. On the other hand, 
our results cannot deny any role of these microorganisms in 
eventual sustenance or acceleration of evident small vessel 
disease, which can only be accomplished with studying cases 
with clinically manifest small vessel cerebrovascular disease. 
However, with the early case fatality rate in small vessel 
stroke being low, such study would not be easy to perform. 
Although signs of small vessel disease were found in 13 of 
our 15 cases, none had clinically manifest disease.  
 In contrast to our findings with PCR and IHC, antibodies 
against C. pneumoniae, CMV and HSV-1 were found in the 
majority of the cases. This concurs with the prevalence of 
these antibodies in a general population. Positive antibody 
titres do not predict the presence of microorganisms in the 
vascular wall of cases, whereas the opposite is also true [36].  
CONCLUSIONS 
 We were unable to detect C. pneumoniae, CMV or HSV-
1 in atherosclerotic large cerebral vessels, despite the pres-
ence of moderate to severe atherosclerotic changes in these 
vessels. Except for one case, in which C. pneumoniae and 
CMV were found in a sample of basal ganglia and periven-
tricular white matter, this was also the case with respect to 
the cerebral small vessels. Our findings suggest a limited 
role for C. pneumoniae, CMV and HSV-1 in large and small 
vessel atherosclerosis. Whether these microorganisms play a 
significant role in symptomatic cerebral LVD and different 
types of SVD needs to be determined in further studies. 
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